Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
暂无分享,去创建一个
P. Libby | P. Ridker | J. Kastelein | J. Foody | D. Mason | K. Ray | S. Nissen | D. Brennan | Stephen J. Nicholls | V. Menon | L. Cho | L. Laffin | A. Lincoff | M. J. Louie | Na Li
[1] A. Pandey,et al. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. , 2023, JAMA cardiology.
[2] D. Grobbee,et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. , 2023, The New England journal of medicine.
[3] K. O'Brien,et al. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. , 2022, JAMA internal medicine.
[4] P. Libby,et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. , 2020, American heart journal.
[5] G. Hankey,et al. Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.
[6] R. Diaz,et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.
[7] A. Khera,et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[8] Jennifer G. Robinson,et al. Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry , 2019, Journal of the American Heart Association.
[9] M. Puhan,et al. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease , 2018, Annals of Internal Medicine.
[10] C. Ballantyne,et al. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry–Practice Innovation and Clinical Excellence Registry , 2018, Circulation. Cardiovascular quality and outcomes.
[11] Jennifer G. Robinson,et al. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry , 2017, American heart journal.
[12] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[13] J. Spertus,et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide , 2017, JAMA cardiology.
[14] B. Nordestgaard,et al. Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014. , 2017, Atherosclerosis.
[15] S. Yusuf,et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.
[16] M. Farkouh,et al. Statin Underuse and Low Prevalence of LDL-C Control Among U.S. Adults at High Risk of Coronary Heart Disease , 2014, The American journal of the medical sciences.
[17] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.
[18] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[19] N. Cook,et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.
[20] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[21] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[22] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[23] Mitchell H Katz,et al. Statins for Primary Prevention: The Debate Is Intense, but the Data Are Weak. , 2017, JAMA internal medicine.
[24] S. Ebrahim,et al. Statins for the primary prevention of cardiovascular disease. , 2011, The Cochrane database of systematic reviews.